The Innovative Medicines Initiative has just published the final review of the IMI1 programme, and the mid-term review of IMI2.

The experts conclude that IMI programme ‘remains relevant and justified’ and that ‘positive contributions on the drug development process have been realised’. Positive points recognised in the reports include:

- the IMI role in the creation of collaborative research networks that have enhanced trust between partners from different sectors, and triggered a mind shift as partners came to understand each other’s needs;

- the quality of the research emerging from IMI projects;

- the creation of important resources and tools for drug development, some of which are already being used by researchers in their daily work.

The reports also note that 90% of the people who responded to the online survey agreed that the EU should cooperate with industry in the context of a public-private partnership on health.

Suggestions for improvement concern performance indicators, increasing the involvement of SMEs as well as dissemination and communication of the projects' results.

Read the European Commission's press release on the evaluation

Read the new IMI brochure on results and impacts

Source: IMI

Tags: